CHMFL-ABL-053

Cat. No.:	HY-101268
CAS No.:	1808287-83-3
Molecular Formula:	$C_{28}H_{26}F_3N_7O_2$
Molecular Weight:	549.55
Target:	Bcr-Abl; Src; p38 MAPK
Pathway:	Protein Tyrosine Kinase/RTK; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC_{50} values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively[1].		
IC_{50} & Target	p38 62 nM (IC_{50})	Abl 70 nM (IC_{50})	SRC 90 nM (IC_{50})
In Vitro	CHMFL-ABL-053 (Compound 18a) inhibits the proliferation of CML cell lines with GI_{50} of 14, 25 and 16 nM against K562, KU812 and MEG-01, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
In Vivo	CHMFL-ABL-053 (Compound 18a) (50 mg/kg/day) almost completely suppresses tumor progression in the K562 cells inoculated xenograft mouse model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Liang X, et al. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. J Med Chem. 2016 Mar 10;59(5):1984-2004.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA